A PHASE I, 2-PART STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF INTRATHECALLY ADMINISTERED RG6496 IN A RANDOMIZED, PLACEBO-CONTROLLED, INVESTIGATOR/PARTICIPANT-BLIND STUDY WITH AN OPEN-LABEL EXTENSION IN HUNTINGTON'S DISEASE GENE EXPANSION CARRIERS
- Registry ID
- BP45378
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2026-05-12
- Last update
- 2025-10-17
Conditions
Related clinical trials
- A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF VOTOPLAM IN PARTICIPANTS WITH HUNTINGTON’S DISEASE
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, TO EVALUATE THE
SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF
INTRATHECALLY ADMINISTERED SINGLE ASCENDING DOSES OF ALN-HTT02 IN
ADULT PATIENTS WITH HUNTINGTON'S DISEASE
- A PHASE 2B, DOUBLE-BLIND, RANDOMIZED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF VOTOPLAM IN PARTICIPANTS WITH HUNTINGTON'S DISEASE
- LONG-TERM STUDY TO EVALUATE SAFETY AND TOLERABILITY OF VALBENAZINE IN PATIENTS WITH CHOREA ASSOCIATED WITH HUNTINGTON DISEASE IN CANADA
- A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO INVESTIGATE THE SAFETY, BIOMARKERS, AND EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL AND EARLY MANIFEST HUNTINGTON'S DISEASE
- A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY IN SUBJECTS WITH LATE PRODROMAL AND EARLY MANIFEST HUNTINGTON DISEASE (HD) TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VX15/2503
View on source registry